News

Newsletter

13 de April de 2013

Newsletter 2013.02 – Recent developments regarding examination of pharma patent applications

Brazilian PTO’s new Resolution No. 80 of March 19, 2013 sets forth rules for granting priority examination for patent applications related to pharmaceutical products and processes, and equipments and materials related to public health

The Brazilian PTO published Resolution No. 80, on March 19, 2013 in the Official Gazette, which establishes the proceedings for requesting priority examination of patent applications related to pharmaceutical products and processes, and equipments and materials related to public health. We are pleased to hereby enclose a complete English language version of the resolution for your review.

According to the new resolution, now in full force, priority for the examination of patent applications related to public health may be requested by:

Back

Last related news

9 de December de 2025

Fake Software Resellers: A Growing Risk for Users and a New Front in IP Enforcement

For years, the most common form of software piracy involved downloading cracked or unauthorized versions from websites offering them for free. Although Fake Software Resellers: A Growing Risk for Users and a New Front in IP Enforcement

  • Kasznar Leonardos
  • Ler notícia

    25 de November de 2025

    Significant Win for Kasznar Leonardos as Appellate Court Raises Compensation in Software Infringement Case

    Kasznar Leonardos is pleased to announce an important victory before the São Paulo Court of Appeals in a software license compliance action Significant Win for Kasznar Leonardos as Appellate Court Raises Compensation in Software Infringement Case

  • Kasznar Leonardos
  • Ler notícia

    13 de November de 2025

    ANVISA Publishes Exceptional Rule to Expedite Analysis of Medicines and Biological Products

    The National Health Surveillance Agency (Anvisa) published on Monday, November 10, 2025, the Collegiate Board Resolution (RDC) No. 997/2025, which institutes exceptional ANVISA Publishes Exceptional Rule to Expedite Analysis of Medicines and Biological Products

  • Kasznar Leonardos
  • Ler notícia